Paper · 28770320
FGF21 improves glucose homeostasis in an obese diabetes-prone mouse model independent of body fat changes.
Laeger T and 5 others. Diabetologia, 2017. Cited by 44 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. FGF21 improves glucose homeostasis in an obese diabetes-prone mouse model independent of body fat changes. Papers, record 28770320. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28770320
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- FGF21 improves glucose homeostasis in an obese diabetes-prone mouse model independent of body fat changes.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Fibroblast Growth Factors | Major topic |
| Glucose | Major topic |
| Obesity | Major topic |
| Adipose Tissue, Brown | |
| Adipose Tissue, White | |
| Animals | |
| Energy Metabolism | |
| Insulin Resistance | |
| Male | |
| Mice | |
| Mice, Obese | |
| Thermogenesis |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| LA 3042/4-1 | Deutsche Forschungsgemeinschaft | PubMed | ||
| 82DZD00302 | German Ministry of Education and Research and the Brandenburg State | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References48
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20,357,365 | Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. | Diabetes | 2010 | https://conductscience.org/library/papers/20357365 | PubMed |
| 2 | 23,823,755 | LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys. | PLoS One | 2013 | https://conductscience.org/library/papers/23823755 | PubMed |
| 3 | 23,766,126 | Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. | Endocrinology | 2013 | https://conductscience.org/library/papers/23766126 | PubMed |
| 4 | 21,846,717 | Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes. | J Biol Chem | 2011 | https://conductscience.org/library/papers/21846717 | PubMed |
| 5 | 25,414,019 | Head over hepatocytes for FGF21. | Diabetes | 2014 | https://conductscience.org/library/papers/25414019 | PubMed |
| 6 | 19,706,786 | Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects. | Am J Physiol Endocrinol Metab | 2009 | https://conductscience.org/library/papers/19706786 | PubMed |
| 7 | 26,872,145 | Fibroblast Growth Factor 21 (FGF21) Protects against High Fat Diet Induced Inflammation and Islet Hyperplasia in Pancreas. | PLoS One | 2016 | https://conductscience.org/library/papers/26872145 | PubMed |
| 8 | 28,580,290 | FGF21 resistance is not mediated by downregulation of beta-klotho expression in white adipose tissue. | Mol Metab | 2017 | https://conductscience.org/library/papers/28580290 | PubMed |
| 9 | 27,878,865 | Fibroblast growth factor 21 night watch: advances and uncertainties in the field. | J Intern Med | 2017 | https://conductscience.org/library/papers/27878865 | PubMed |
| 10 | 18,252,893 | Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. | Diabetes | 2008 | https://conductscience.org/library/papers/18252893 | PubMed |
1 to 10 of 48
See all 48 referencesCited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 44 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,957,849 | Biological functions and emerging interplay of FGF21 and GDF15 in metabolic diseases and aging. | Mol Biomed | 2026 | https://conductscience.org/library/papers/42957849 | PubMed |
| 42,625,697 | Epigenetics, bacterial metabolites and type 2 diabetes: a new view of gut-genome interactions. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42625697 | PubMed |
| 42,313,341 | The role of fibroblast growth factor 21 in diabetes and metabolic dysfunction. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42313341 | PubMed |
| 40,237,521 | Housing Temperature Impacts the Systemic and Tissue-Specific Molecular Responses to Cancer in Mice. | J Cachexia Sarcopenia Muscle | 2025 | https://conductscience.org/library/papers/40237521 | PubMed |
| 39,757,236 | Effects of exercise intensity and diet on cardiac tissue structure and FGF21/β-Klotho signaling in type 2 diabetic mice: a comparative study of HFD and HFD + STZ induced type 2 diabetes models in mice. | Diabetol Metab Syndr | 2025 | https://conductscience.org/library/papers/39757236 | PubMed |
| 39,618,173 | The role of the glucagon-FGF21 axis in improving beta cell function during glucose intolerance and SGLT2 inhibition. | Diabetes Obes Metab | 2025 | https://conductscience.org/library/papers/39618173 | PubMed |
| 39,412,985 | Hepatocyte Period 1 dictates oxidative substrate selection independent of the core circadian clock. | Cell Rep | 2024 | https://conductscience.org/library/papers/39412985 | PubMed |
| 38,957,656 | Defective FGFR1 Signaling Disrupts Glucose Regulation: Evidence From Humans With FGFR1 Mutations. | J Endocr Soc | 2024 | https://conductscience.org/library/papers/38957656 | PubMed |
| 38,323,454 | Targeted Proteomics Reveals Functional Targets for Early Diabetes Susceptibility in Young Adults. | Circ Genom Precis Med | 2024 | https://conductscience.org/library/papers/38323454 | PubMed |
| 38,244,215 | FGF21 Induces Skeletal Muscle Atrophy and Increases Amino Acids in Female Mice: A Potential Role for Glucocorticoids. | Endocrinology | 2024 | https://conductscience.org/library/papers/38244215 | PubMed |
1 to 10 of 32
See all 32 cited byGenes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| FGF21 | 26,291 | PubTator's text mining | https://conductscience.org/library/genes/26291 | NCBI Gene |
| INS | 3,630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
| KLB | 152,831 | PubTator's text mining | https://conductscience.org/library/genes/152831 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28770320
GET https://conductscience.org/api/papers/v1/28770320/references?page=2